I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a US-based global clinical-stage biotech company focused on developing immunotherapies for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The company's management team, including Interim CEO Sean Fu and CMO Phillip Dennis, will present at 5:00 PM ET.

The event will also feature one-on-one and small group meetings from September 9-10, with additional management participants including CFO Joe Skelton and Senior Director of Investor Relations Tyler Ehler. A webcast of the presentation will be available on I-Mab's IR website under the 'Event Calendar' section.

News Market Reaction

+7.00%

1 alert

+7.00% News Effect

On the day this news was published, IMAB gained 7.00%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.

H.C. Wainwright 26th Annual Global Investment Conference

Presentation Time	Tuesday, September 10 at 5:00 PM ET
Presenters	Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)
Webcast link	Here
Meetings	One-on-one and small group meetings: September 9 – 10, 2024
Management Participants	Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR website
at https://ir.i-mabbiopharma.com/

For more information, please contact your H.C. Wainwright representative.

About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact: 
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-hc-wainwright-26th-annual-global-investment-conference-302230144.html

SOURCE I-Mab Biopharma

FAQ

When is I-Mab (IMAB) presenting at the H.C. Wainwright Global Investment Conference?

I-Mab (IMAB) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 5:00 PM ET.

Who will be presenting for I-Mab (IMAB) at the conference?

Sean Fu, PhD, Interim CEO, and Phillip Dennis, MD, PhD, Chief Medical Officer, will be presenting for I-Mab (IMAB) at the conference.

What type of meetings will I-Mab (IMAB) be conducting at the conference?

I-Mab (IMAB) will be conducting one-on-one and small group meetings on September 9-10, 2024, during the H.C. Wainwright conference.

Where can investors access the webcast of I-Mab's (IMAB) presentation?

Investors can access the webcast of I-Mab's (IMAB) presentation under the 'Event Calendar' section on I-Mab's IR website at https://ir.i-mabbiopharma.com/